Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Making Artificial Intelligence systems robustly perceive humans remains one of the most intricate challenges in computer ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...